Skip to main content
Gemtuzumab ozogamycin heightens risk for toxicities with no survival benefit in de novo AML
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Gemtuzumab ozogamycin heightens risk for toxicities with no survival benefit in de novo AML
User login
Username
Password
Reset your password
concept
Lead
score
Acute Leukemia
1
1
Specialty
Lead
score
Hematology-Oncology
1
1